{"id":"NCT03159104","sponsor":"Materia Medica Holding","briefTitle":"Efficacy and Safety of Tenoten for Children in the Treatment of Specific Developmental Disorders of Scholastic Skills in Children","officialTitle":"Multicenter Double-blind Placebo-Controlled Randomized Clinical Trial of Efficacy and Safety of Tenoten for Children in the Treatment of Specific Developmental Disorders of Scholastic Skills in Children","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08-25","primaryCompletion":"2019-02-18","completion":"2019-02-18","firstPosted":"2017-05-18","resultsPosted":"2023-08-21","lastUpdate":"2023-08-21"},"enrollment":240,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Specific Developmental Disorders of Scholastic Skills"],"interventions":[{"type":"DRUG","name":"Tenoten for children","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tenoten for children","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Purpose of the study:\n\nâ€¢ To evaluate efficacy and safety of Tenoten for children in the treatment of specific developmental disorders of scholastic skills in children.","primaryOutcome":{"measure":"Mean Total Scholastic Skills Score (a Sum of Three Scales: Reading, Spelling, and Counting).","timeFrame":"On Day 1 and after 12 weeks of the therapy","effectByArm":[{"arm":"Tenoten for Children","deltaMin":61.39,"sd":12.04},{"arm":"Placebo","deltaMin":60.46,"sd":11.04}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0113"}]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":122},"commonTop":["ARVI","ARI","Headache","Abdominal pain","Nasopharyngitis"]}}